Mounjaro P — correcting the confusion around this search

The biggest misconception: "P" doesn't mean you can buy it differently

One thing our prescribers hear regularly is the assumption that there's a route to Mounjaro that sidesteps the prescription process, a pharmacy-only version, an over-the-counter option, or some "P" category that makes it easier to obtain. There isn't. Under the Human Medicines Regulations 2012, tirzepatide is classified as a Prescription-Only Medicine regardless of where you buy it, what dose you're after, or how it's described online. That means a qualified prescriber must assess your health, confirm you meet the licensed criteria, and issue a valid prescription before any pen can be dispensed. This isn't a bureaucratic inconvenience, it's a safety structure, and it matters. If you come across a seller offering Mounjaro without that process, the MHRA has been explicit: report it via the Yellow Card scheme. Counterfeit pens seized across the UK have included entirely different substances, and the harm from them has been real.

So if you've been searching for "Mounjaro p" hoping to find a simpler path, the honest answer is that the prescription route is the only legitimate one, and if you want to understand what Mounjaro y refers to and how it fits into the wider picture, through a regulated service it can be considerably more straightforward than people expect.

What Mounjaro actually does, and why the two-receptor point matters

Tirzepatide activates both the GIP receptor and the GLP-1 receptor. Both are involved in signalling fullness to the brain and slowing the rate at which food leaves the stomach; together, they also influence how the body handles blood sugar. The dual-pathway mechanism is what separates Mounjaro from older GLP-1 medicines, and it's reflected in the trial results. In the SURMOUNT-1 study, participants taking the 15 mg dose lost around 20–21% of their body weight on average over 72 weeks alongside a reduced-calorie diet and increased activity, findings reported in the New England Journal of Medicine. That figure is an average from a controlled trial; individual results vary, and no one can predict in advance exactly how much weight any particular person will lose. What the evidence does confirm is a meaningful, clinically significant effect at the population level, which is why NICE recommended tirzepatide in December 2024 for eligible adults in England.

The medicine is taken as a once-weekly subcutaneous injection via a pre-filled KwikPen. Each pen holds four doses. Treatment begins at 2.5 mg (a dose designed to let your system adjust, not to produce weight loss on its own) and is increased by your prescriber in a structured way over subsequent months, and if you are curious about what that step up involves, our page covering Mounjaro 2 goes into the detail of that early stage. You can read more about how the full Mounjaro treatment is structured if you want a broader overview.

Who the licence covers, and what the prescriber looks at

The licensed indications for Mounjaro in the UK cover adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related health condition. Relevant conditions include type 2 diabetes, high blood pressure, raised cholesterol, obstructive sleep apnoea and cardiovascular disease, among others. Lower BMI thresholds can apply for some ethnic backgrounds under current UK guidance. A prescriber doesn't just check a BMI number, though, they look at your full health picture, including any medicines you already take, your medical history, and conditions that might make this treatment unsuitable. Pregnancy, breastfeeding, trying to conceive and being under 18 are all situations where Mounjaro is not recommended. If you want a sense of the typical questions a consultation covers before thinking about cost, the Mounjaro pricing page explains what a legitimate private prescription includes. For those curious about a specific dose in the titration pathway, the 5 mg pen page covers that stage in detail.

Side effects to know about before you decide

The most common side effects are gastrointestinal: nausea, loose stools, constipation, indigestion, and burping tend to be most noticeable in the first weeks after starting or following a dose increase, and they generally ease as the body adjusts. Fatigue and headaches are also reported. More serious but less common concerns include acute pancreatitis, the MHRA has highlighted severe, persistent stomach pain that might radiate to the back as a symptom requiring urgent medical attention. Gallbladder problems, dehydration from prolonged GI symptoms, and allergic reactions are also listed in the summary of product characteristics. None of this is to alarm you. Knowing what to watch for, and having a prescriber to contact when something feels off, is exactly why clinical oversight is built into every step of a legitimate prescription service. Our weight-loss treatment page explains how that aftercare works at nume, and our clinical team is available to answer questions seven days a week. If you'd like to understand the broader landscape of weight-loss treatment options before committing to a consultation, that's a sensible place to start.